Adial Pharmaceuticals, Inc. (ADIL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Adial Pharmaceuticals, Inc. (ADIL) closed at USD 3.00 on 2026-10-14, a change of -68.4 % over the past year, with a market capitalization of USD 8.25M.

Adial Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Adial Pharmaceuticals, Inc. key figures

Previous close

USD 3.00 (2026-10-14)

1-year change

-68.4 %

Market cap

USD 8.25M

Enterprise value

USD 18.07M

P/E ratio (trailing)

-0.16

P/E ratio (forward)

-0.42

EPS (trailing)

-19.59

EPS (forward)

-7.45

PEG ratio

n/a

Price to book

-0.21

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.79

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Adial Pharmaceuticals, Inc. and compare it with other stocks.